[Personalized treatment in non-small cell lung cancer].

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 23227588
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

  2011cited by this paper
• Afatinib (BIBW 2992) development in non-small-cell lung cancer.

  2011cited by this paper
• Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

  2011cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• EGFR T790M mutation: a double role in lung cancer cell survival?

  2009cited by this paper
• The role of EGFR inhibition in the treatment of non-small cell lung cancer.

  2009cited by this paper
• Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

  2009cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

  2008cited by this paper
• Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study

  2008cited by this paper
• A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway

  2006cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

  2005cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

  2004cited by this paper
• Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

  2003cited by this paper
• Smoking molecular damage in bronchial epithelium

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Oncogene regulation by growth factors.

  1993cited by this paper

• SOX2 Promotes Radioresistance in Non-small Cell Lung Cancer by Regulating Tumor Cells Dedifferentiation

  2023cites this paper
• Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices

  2018cites this paper
• Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

  2018cites this paper
• Factores que influyen en la demora diagnóstica de la neoplasia de pulmón en egresados vivos

  2018cites this paper
• Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial

  2016cites this paper
• Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer

  2016cites this paper
• Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico

  2015cites this paper
• [National consensus of diagnosis and treatment of non-small cell lung cancer].

  2013cites this paper